140 related articles for article (PubMed ID: 9275034)
1. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer.
Buzio C; De Palma G; Passalacqua R; Potenzoni D; Ferrozzi F; Cattabiani MA; Manenti L; Borghetti A
Br J Cancer; 1997; 76(4):541-4. PubMed ID: 9275034
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
[TBL] [Abstract][Full Text] [Related]
3. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
6. [Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer].
Jurincic-Winkler C; Horlbeck R; Klippel KF
Wien Klin Wochenschr; 1993; 105(10):271-6. PubMed ID: 8517056
[TBL] [Abstract][Full Text] [Related]
7. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
Schomburg A; Kirchner H; Atzpodien J
Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
[TBL] [Abstract][Full Text] [Related]
8. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
9. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.
Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A
Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283
[TBL] [Abstract][Full Text] [Related]
10. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
Finck-Seelen ; Lampert R; Brandt L
Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
[TBL] [Abstract][Full Text] [Related]
11. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
12. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
Atzpodien J; Kirchner H; Duensing S; Lopez Hänninen E; Franzke A; Buer J; Probst M; Anton P; Poliwoda H
World J Urol; 1995; 13(3):174-7. PubMed ID: 7550391
[TBL] [Abstract][Full Text] [Related]
13. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
[TBL] [Abstract][Full Text] [Related]
14. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group.
Rogers E; Bredin H; Butler M; Corcoran M; Egan E; Fennelly J; Grainger R; Aleer SM; Dermott TM; Mullins G; Tanner A; Twomey A; Thornhill J
Eur Urol; 2000 Mar; 37(3):261-6. PubMed ID: 10720849
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
Pavone L; Andrulli S; Santi R; Majori M; Buzio C
Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.
Facendola G; Locatelli MC; Pizzocaro G; Piva L; Pegoraro C; Pallavicini EB; Signaroldi A; Meregalli M; Lombardi F; Beretta GD
Br J Cancer; 1995 Dec; 72(6):1531-5. PubMed ID: 8519672
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study.
Atzpodien J; Kirchner H; de Mulder P; Bodenstein H; Oliver T; Palmer PA; Franks CR; Poliwoda H
Cancer Biother; 1993; 8(4):289-300. PubMed ID: 7804370
[TBL] [Abstract][Full Text] [Related]
20. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
